**Core Concept**
The bivalent HPV vaccine is designed to protect against two high-risk human papillomavirus (HPV) types, which are responsible for causing cervical cancer and other anogenital cancers. This vaccine type is particularly useful for countries with limited resources, as it targets the most common HPV types found in these regions.

**Why the Correct Answer is Right**
The bivalent HPV vaccine contains HPV types 16 and 18, which are responsible for approximately 70% of cervical cancer cases worldwide. These two types are the most common high-risk HPV types and are associated with a high risk of developing cervical cancer. The vaccine works by inducing an immune response against these two types, providing protection against future infections.

**Why Each Wrong Option is Incorrect**
**Option A:** This option is incorrect as it does not specify the correct HPV types contained in the bivalent vaccine. While HPV types 6 and 11 are also high-risk types, they are not the primary targets of the bivalent vaccine.
**Option B:** This option is incorrect as it is not a specific type of HPV vaccine that targets two high-risk types. Quadrivalent and nonavalent vaccines also exist but have different targets.
**Option C:** This option is incorrect as it does not accurately list the correct HPV types contained in the bivalent vaccine.

**Clinical Pearl / High-Yield Fact**
The bivalent HPV vaccine is an effective tool in preventing cervical cancer, particularly in regions with limited resources. It is essential to remember that this vaccine targets the most common high-risk HPV types, making it a valuable addition to cervical cancer prevention strategies.

**Correct Answer:** HPV types 16 and 18.